United Kingdom · Question · Written question
UIN 96433
Glioblastoma: Immunotherapy
Original
Introduced
2 December 2025
Last action
8 December 2025 · Answer
Status
Answered
Sponsors
—
Subjects
Discovery layer
Source updated
8 December 2025
Summary
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential merits of DCVax-L following its trial at King’s College Hospital.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
2 December 2025
Written question
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential merits of DCVax-L following its trial at King’s College Hospital.
Source: Commons
8 December 2025
Answer
The Department has made no assessment of the potential merits of DCVax-L following its trial at King’s College Hospital.Northwest Biotherapeutics has submitted a Marketing Authorisation Application to the Medicines and Healthcare products Regulatory Agenc...
Source: Written answer
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Sponsors
- · Department of Health and Social Care · Answering body
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://questions-statements.parliament.uk/written-questions/detail/2025-12-02/96433
- Open data entity: https://questions-statements-api.parliament.uk/api/writtenquestions/questions/1859320
- uk · wq-1859320 · source updated 8 December 2025